MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

MicroRNAs (miRNAs) are small non-coding RNA molecules acting as post-transcriptional regulators of gene expression. They are involved in many biological processes, and their dysregulation is implicated in various diseases, including multiple sclerosis (MS). Interferon-beta (IFN-beta) is widely used as a first-line immunomodulatory treatment of MS patients. Here, we present the first longitudinal study on the miRNA expression changes in response to IFN-beta therapy. Peripheral blood mononuclear cells (PBMC) were obtained before treatment initiation as well as after two days, four days, and one month, from patients with clinically isolated syndrome (CIS) and patients with relapsing-remitting MS (RRMS). We measured the expression of 651 mature miRNAs and about 19,000 mRNAs in parallel using real-time PCR arrays and Affymetrix microarrays. We observed that the up-regulation of IFN-beta-responsive genes is accompanied by a down-regulation of several miRNAs, including members of the mir-29 family. These differentially expressed miRNAs were found to be associated with apoptotic processes and IFN feedback loops. A network of miRNA-mRNA target interactions was constructed by integrating the information from different databases. Our results suggest that miRNA-mediated regulation plays an important role in the mechanisms of action of IFN-beta, not only in the treatment of MS but also in normal immune responses. miRNA expression levels in the blood may serve as a biomarker of the biological effects of IFN-beta therapy that may predict individual disease activity and progression.

[1]  L. Giudice,et al.  Interferon-related and other immune genes are downregulated in peripheral blood leukocytes in the luteal phase of the menstrual cycle. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  R. Aharonov,et al.  Identification of hundreds of conserved and nonconserved human microRNAs , 2005, Nature Genetics.

[3]  K. Ansel,et al.  MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. , 2011, Immunity.

[4]  T. Alber,et al.  tRNA binding, structure, and localization of the human interferon-induced protein IFIT5. , 2013, Molecular cell.

[5]  K. Tufekci,et al.  MicroRNAs and Multiple Sclerosis , 2010, Autoimmune diseases.

[6]  M. Burns,et al.  Modelling the limit of detection in real-time quantitative PCR , 2008 .

[7]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[8]  H. Salamon,et al.  IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  Timos K. Sellis,et al.  miRGen 2.0: a database of microRNA genomic information and regulation , 2009, Nucleic Acids Res..

[10]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[11]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[12]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[13]  N. Putzki,et al.  The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination , 2011, Therapeutic advances in neurological disorders.

[14]  S. Bronk,et al.  Transcriptional suppression of mir‐29b‐1/mir‐29a promoter by c‐Myc, hedgehog, and NF‐kappaB , 2010, Journal of cellular biochemistry.

[15]  H. Alder,et al.  miRNA profiling for biomarker discovery in multiple sclerosis: From microarray to deep sequencing , 2012, Journal of Neuroimmunology.

[16]  M. Hecker,et al.  Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy. , 2011, Pharmacogenomics.

[17]  Christoph Rodak,et al.  MirZ: an integrated microRNA expression atlas and target prediction resource , 2009, Nucleic Acids Res..

[18]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[19]  S. Dhib-jalbut,et al.  Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.

[20]  M. Hecker,et al.  Molecular Biomarkers in Multiple Sclerosis , 2013 .

[21]  J. Clements,et al.  MicroRNA Regulation of IFN-β Protein Expression: Rapid and Sensitive Modulation of the Innate Immune Response , 2010, The Journal of Immunology.

[22]  R Guthke,et al.  Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment , 2010, The Pharmacogenomics Journal.

[23]  H. Weiner,et al.  Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis , 2013, Annals of neurology.

[24]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[25]  Olaf Wolkenhauer,et al.  Computational analysis of target hub gene repression regulated by multiple and cooperative miRNAs , 2012, Nucleic acids research.

[26]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[27]  Olaf Wolkenhauer,et al.  Web resources for microRNA research. , 2013, Advances in experimental medicine and biology.

[28]  Hans-Peter Lenhof,et al.  Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls , 2009, PloS one.

[29]  D. Cooper,et al.  Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression , 2012, The Journal of Immunology.

[30]  Charles D. Johnson,et al.  Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. , 2007, Cancer research.

[31]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[32]  A. D. dos Santos,et al.  miR-15a and 16-1 Are Downregulated in CD4+ T Cells of Multiple Sclerosis Relapsing Patients , 2012, The International journal of neuroscience.

[33]  B. Hemmer,et al.  Treatment of multiple sclerosis: current concepts and future perspectives , 2011, Journal of Neurology.

[34]  H. Lassmann,et al.  MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. , 2009, Brain : a journal of neurology.

[35]  V. Martinelli,et al.  MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers , 2012, Neuroscience Letters.

[36]  Yan-Yan Zhang,et al.  MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. , 2010 .

[37]  Michael Hecker,et al.  Integrative modeling of transcriptional regulation in response to antirheumatic therapy , 2009, BMC Bioinformatics.

[38]  L. Notterpek,et al.  Peripheral myelin protein 22 is regulated post‐transcriptionally by miRNA‐29a , 2009, Glia.

[39]  Dirk Koczan,et al.  Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance , 2012, Journal of Neuroinflammation.

[40]  Klaus Rajewsky,et al.  MicroRNA Control in the Immune System: Basic Principles , 2009, Cell.

[41]  L. Kappos,et al.  Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. , 2012, Clinical immunology.

[42]  Heidi J. Peltier,et al.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. , 2008, RNA.

[43]  Xiongfei Xu,et al.  The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ , 2011, Nature Immunology.

[44]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[45]  Dirk Koczan,et al.  Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. , 2010, Pharmacogenomics.

[46]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[47]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[48]  Hanah Margalit,et al.  RepTar: a database of predicted cellular targets of host and viral miRNAs , 2010, Nucleic Acids Res..

[49]  M. Hecker,et al.  Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis , 2012, Molecular Neurobiology.

[50]  D. Galimberti,et al.  Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis , 2013, International journal of molecular sciences.

[51]  Mark S. Freedman,et al.  Therapy of MS , 2010, Clinical Neurology and Neurosurgery.

[52]  David H. Miller,et al.  Clinically isolated syndromes , 2012, The Lancet Neurology.

[53]  C. Polman,et al.  Determinants of interferon β efficacy in patients with multiple sclerosis , 2011, Nature Reviews Neurology.

[54]  R. Malenka,et al.  An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration , 2012, Nature Neuroscience.

[55]  M. Atiya,et al.  Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis , 2011, PloS one.

[56]  R. Gold,et al.  Regulated microRNAs in the CSF of patients with multiple sclerosis , 2012, Neurology.

[57]  Chi-Ying F. Huang,et al.  miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..

[58]  Doron Lancet,et al.  Novel definition files for human GeneChips based on GeneAnnot , 2007, BMC Bioinformatics.

[59]  J. A. Lozano,et al.  Differential Micro RNA Expression in PBMC from Multiple Sclerosis Patients , 2009, PloS one.

[60]  M. Hecker,et al.  MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2012, Autoimmunity reviews.

[61]  K. Selmaj,et al.  microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination , 2012, Proceedings of the National Academy of Sciences.

[62]  A. Bertolotto,et al.  Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis , 2005, Journal of Neuroimmunology.

[63]  A. Pasquinelli,et al.  MicroRNA assassins: factors that regulate the disappearance of miRNAs , 2010, Nature Structural &Molecular Biology.

[64]  Giulio Superti-Furga,et al.  Structural basis for viral 5′-PPP-RNA recognition by human IFIT proteins , 2013, Nature.

[65]  Dirk Koczan,et al.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood , 2013, Molecular Neurobiology.

[66]  P. Kenny,et al.  MicroRNAs in neuronal function and dysfunction , 2012, Trends in Neurosciences.

[67]  E. Borden,et al.  Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[68]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[69]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[70]  Thomas Preiss,et al.  Circular RNAs: splicing's enigma variations , 2013, The EMBO journal.

[71]  L. Kappos,et al.  Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients , 2010, European journal of immunology.

[72]  C. Croce,et al.  miR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis , 2012, The Journal of Immunology.